|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.13 USD | -1.35% |
|
-0.49% | +13.73% |
| Capitalization | 115B 109B 101B 90.08B 162B 9,724B 180B 1,253B 463B 3,995B 431B 422B 17,214B | P/E ratio 2024 * |
997x | P/E ratio 2025 * | 16.3x |
|---|---|---|---|---|---|
| Enterprise value | 133B 125B 116B 104B 187B 11,222B 207B 1,446B 535B 4,611B 498B 487B 19,866B | EV / Sales 2024 * |
4.68x | EV / Sales 2025 * | 4.53x |
| Free-Float |
-
| Yield 2024 * |
3.33% | Yield 2025 * | 3.5% |
More valuation ratios
* Estimated data
More news
Last Transcript: Gilead Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | -1.35% | ||
| 1 week | -0.49% | ||
| Current month | -0.49% | ||
| 1 month | -4.59% | ||
| 3 months | +17.04% | ||
| 6 months | +42.40% | ||
| Current year | +13.73% |
1 week
89.86
94.39
1 month
86.0898.90
Current year
62.0798.90
1 year
62.0798.90
3 years
57.1798.90
5 years
56.5698.90
10 years
56.56123.37
| Director | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 28/02/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 31/10/2019 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 11/04/2021 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 56 | 18/08/2016 |
| Director/Board Member | 71 | 31/12/2017 | |
| Director/Board Member | 70 | 08/05/2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 380 M€ | +9.14% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.35% | -0.49% | +16.59% | +32.16% | 115B | ||
| +0.13% | +3.94% | +38.23% | +238.37% | 744B | ||
| +1.88% | +3.72% | +17.48% | +112.70% | 493B | ||
| -0.14% | -3.68% | -3.31% | -9.15% | 359B | ||
| +0.01% | -3.68% | +18.03% | +44.57% | 311B | ||
| -0.44% | +1.43% | -0.64% | +40.81% | 261B | ||
| +0.27% | +0.59% | +1.46% | -31.08% | 235B | ||
| +0.34% | +0.40% | +5.26% | +28.61% | 211B | ||
| -0.63% | -3.71% | +6.01% | +20.03% | 205B | ||
| -0.64% | -3.64% | +1.29% | +27.65% | 147B | ||
| Average | -0.06% | -0.51% | +10.04% | +50.47% | 308.06B | |
| Weighted average by Cap. | +0.20% | +0.50% | +14.97% | +85.94% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 28.31B 26.79B 24.83B 22.21B 40.02B 2,397B 44.3B 309B 114B 985B 106B 104B 4,244B | 28.29B 26.78B 24.82B 22.2B 40B 2,396B 44.28B 309B 114B 985B 106B 104B 4,242B |
| Net income | 259M 245M 227M 203M 367M 21.96B 406M 2.83B 1.05B 9.02B 974M 952M 38.87B | 6.92B 6.55B 6.07B 5.43B 9.79B 586B 10.83B 75.54B 27.93B 241B 26B 25.42B 1,038B |
| Net Debt | 17.69B 16.74B 15.52B 13.88B 25.01B 1,498B 27.68B 193B 71.38B 615B 66.45B 64.97B 2,652B | 13.37B 12.65B 11.73B 10.49B 18.9B 1,132B 20.92B 146B 53.94B 465B 50.22B 49.1B 2,004B |
More financial data
* Estimated data
Employees
18,000
Sector
Pharmaceuticals
Calendar
12/12/2024
- Détachement de
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/12/24 | 92.13 $ | -1.35% | 4,470,730 |
| 05/12/24 | 93.39 $ | +1.97% | 12,428,734 |
| 04/12/24 | 91.59 $ | -0.97% | 9,124,340 |
| 03/12/24 | 92.49 $ | -1.63% | 5,532,434 |
| 02/12/24 | 94.02 $ | +1.56% | 5,023,289 |
Delayed Quote Nasdaq, December 06, 2024 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
92.13USD
Average target price
97.85USD
Spread / Average Target
+6.21%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GILD Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition